M. Kathleen Behrens, Director at IGM Biosciences, Inc. (IGMS), bought 60,000 shares at $17.14 ($1.0M) on 2022-11-08, disclosed to the SEC on 2022-11-10.
Open-market purchase of $1.0M IGMS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| SRPT | SELL | 2021-03-10 | $429K | — | Filing → |
| IGMS | BUY | 2020-12-15 | $3.0M | — | Filing → |
| IGMS | BUY | 2020-09-14 | $3.2M | — | Filing → |